ZD-4190 NEW
| Price | $77 | $193 | $290 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: ZD-4190 | CAS No.: 413599-62-9 |
| Purity: 99.12% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | ZD-4190 |
| Description | ZD-4190 is a compound that inhibits both the vascular endothelial growth factor receptor 2 (VEGFR2) and the epidermal growth factor receptor (EGFR) signaling pathways, utilized in cancer treatment. |
| Animal Research | ZD4190 was administered by gavage suspended in 1% polysorbate 80 at 50 mg/kg 24 h after tumour cell implantation for a maximum of 22 days. Control rodents were gavaged with the vehicle only and a third group was untreated. In preliminary experiments, rodents were killed on alternate days so that the effect of ZD4190 on tumour outgrowth could be assessed and subsequently the treatment response was evaluated at day 9 or 22. At least five rodents were included in each treatment group. |
| In vitro | ZD4190 can prevent outgrowth of malignant cells when the tumour burden is below a critical threshold. |
| In vivo | ZD4190 (100 mg/kg, p.o.) effectively delays MDA-MB-435 tumor growth in mice. In ZD4190-treated tumors, [18F-FPPRGD2] uptake significantly decreased by 26.74 ± 8.12% (p<0.05) on day 1 and by 41.19 ± 6.63% (p<0.01) on day 3, returning to baseline by day 7. Tumor uptake of [18F-FLT] also decreased on days 1 and 3 after initiating ZD4190 treatment. However, ZD4190 did not significantly alter [18F-FDG] uptake compared to the control group. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 20.83 mg/mL (45.35 mM) |
| Keywords | Inhibitor | inhibit | Vascular endothelial growth factor receptor | ZD-4190 | VEGFR | Epidermal growth factor receptor | EGFR | ErbB-1 | ZD4190 | HER1 | ZD 4190 |
| Inhibitors Related | Nintedanib | Osimertinib | Sorafenib | Lapatinib | Regorafenib | Erlotinib hydrochloride | Erlotinib | Neratinib | Genistein | Gefitinib | Pazopanib | Axitinib |
| Related Compound Libraries | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $119.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-13 | |
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY